@AlbertBourla | 57,966 followers
Today, we took another step forward in our prostate cancer research, sharing positive topline results from our global trial for metastatic castration-resistant prostate cancer (mCRPC), a disease greatly in need of new solutions: on.pfizer.com/3M3jxMy

Tweet Engagement Stats

Stats are based upon replies and quotes of this tweet

Engagement Map

Quotes
Replies
Retweets
Trendsmap

Replies and Quotes

Total of 6 replies and 0 quotes found
In reply to @AlbertBourla
mCRPC is a form of advanced prostate cancer that impacts 10%-20% of men within a few years of their initial diagnosis. These patients need a solution, and we are working hard to target the disease in new, effective ways.
 
In reply to @AlbertBourla
"What we really have now is a pandemic of people who can't admit they were wrong."
 
 
In reply to @AlbertBourla
Maybe would've worked out if a vet wasn't in charge of people's health.
 
In reply to @AlbertBourla
The weirdest part of the covid debacle for me has been the realization that a very significant chunk of the population actually enjoys being controlled. So much of what has happened throughout history now makes a bit more sense. We haven’t evolved at all in this regard.
 
In reply to @AlbertBourla
Dr Bourla- how many more months of time to death does this treatment provide?
 

Retweeters

No retweeters found
8 retweeters not shown
For access to this functionality a Trendsmap Explore subscription is required.

A Trendsmap Explore subscription provides full access to all available timeframes

Find out more

Thanks for trying our Trendsmap Pro demo.

For continued access, and to utliise the full functionality available, you'll need to subscribe to a Trendsmap Pro subscription.

Find out more

This account is already logged in to Trendsmap.
Your subscription allows access for one user. If you require access for more users, you can create additional subscriptions.
Please Contact us if you are interested in discussing discounts for 3+ users for your organisation, or have any other queries.